MyVisionTest News Archive

Displaying news items tagged with diabetes (More tags »)
SELECT PAGE
First <<  1 2 3 4 5 6   >> Last

Racial diversity
Jan 16, 2012
The Latino Eye Study identified older age and higher pulse pressure as risk factors for 4-year incidence of age-related macular degeneration (AMD) in adult Latinos. Latinos constitute the largest and fastest-growing minority segment of the US population. If recent trends continue, the US Latino population is estimated to increase to 102.6...

Full Article


National Health Service
Mar 27, 2011
In draft guidance issued this month, the National Institute for Health and Clinical Excellence (NICE) in Britian has not recommended Lucentis (ranibizumab) for treating diabetic macular oedema (DMO). This draft guidance has been issued for consultation. NICE has not yet issued final guidance to the NHS. People with diabetes frequently...

Full Article


Diabetes
Mar 27, 2011
The National electronic Library for Medicines in the European Union (EU) has published a review that summarizes the clinical trial data investigating the safety and effectiveness of Lucentis, Macugen, and Iluvien in the treatment of diabetic macular edema. Diabetic macular edema (DME) is a common manifestation of diabetic retinopathy and can...

Full Article


Diabetes
Mar 8, 2011
Genentech announced today that one of two Phase III studies evaluating monthly Lucentis (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint. DME is a serious complication of diabetes that affects up to 10 percent of people with the disease and can lead to blurred vision, severe vision loss and blindness....

Full Article


Asian family
Feb 26, 2011
Researchers have found a relationship between diabetes mellitus and early age-related macular degeneration in Korean adults, according to a new study. Other than age, the epidemiologic risk factors most consistently associated with AMD are cardiovascular risk factors. Many cardiovascular disease risk factors have been suggested as potential...

Full Article


Diabetic retinopathy
Jan 21, 2011
The European Commission has granted Novartis a new indication for Lucentis (ranibizumab) to treat patients with visual impairment due to diabetic macular edema (DME), a leading cause of blindness in the working-age population in most developed countries. Laser therapy, the current standard of care, has provided stabilization of vision in many...

Full Article


The Iluvien insert, shown on a human finger to indicate size
Jan 20, 2011
Alimera Sciences announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational drug ILUVIEN. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form. The application seeks the approval to...

Full Article


Avastin
Oct 16, 2010
A case report describes development of ischemic maculopathy following treatment of diabetic macular edema with Avastin It has been recently documented that Lucentis causes retinal arteriolar vasoconstiction, and this has the potential to induce or worsen retinal ischemia (oxygen deprivation). It has been suggested that anti-VEGF agents be used...

Full Article


Diabetes
Sep 20, 2010
Two-year results from a phase 2 trial suggest that anti-VEGF therapy reduces retinal thickness and significantly improves visual acuity in patients with diabetic retinopathy. Combination therapy with laser may reduce the number of injections required, as well as further reducing foveal thickness, Dean Eliott, MD, said at the American Society of...

Full Article


The Iluvien insert, shown on a human finger to indicate size
Sep 20, 2010
The U.S. Food and Drug Administration has granted priority review status to Alimera Sciences' new drug application for its Iluvien intravitreal insert, the company announced in a press release. With the priority review status, which accelerates the FDA's standard review time from 10 months to 6 months, Alimera could receive a response for the...

Full Article


SELECT PAGE
First <<  1 2 3 4 5 6   >> Last
Most Popular
Less - past - More